În afara temei aiqbench
Această știre a fost preluată de la o sursă pe care o urmărim, dar nu ține de domeniul AI sau cuantic, așa că nu există o perspectivă aiqbench pentru ea.
Huahai Pharma: Clinical Trial for New Indication of Subsidiary's HB0056 Injection Approved
36Kr learned that Huahai Pharma announced that its subsidiaries Shanghai Huaaotai Biopharmaceutical Co., Ltd. and Huabo Biomedical Technology (Shanghai) Co., Ltd. recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the addition of a chronic obstructive pulmonary disease indication to the HB0056 injection project.
Citește articolul complet pe 36KrSubiecte conexe
IonQ Superion 256 platform aims for quantum chip manufacturing at scale
Quantum Zeitgeist · 8 sept. 2026
Illinois Quantum Park Names Philip Makotyn Deputy CTO
Quantum Zeitgeist · 4 iun. 2026
Fulin Precision: Fire Breaks Out at Subsidiary, No Casualties, Blaze Extinguished
36Kr · 4 nov. 2026
Elon Musk, Anthropic pledge to give away billions of dollars in shares
SiliconANGLE · 19 oct. 2026